Table 1.

Safety evaluations—related adverse events

Finding	ID93
	2 µg	2 µg	2 µg	10 µg	10 µg	10 µg
	GLA-SE
	–	2 µg	5 µg	–	2 µg	5 µg
	n = 6	n = 12	n = 12	n = 6	n = 12	n = 12
Subjects with at least one related AE	3 (50%)	12 (100%)	10 (83%)	2 (33%)	12 (100%)	10 (83%)
Local solicited adverse events
Injection site erythema	0	2 (17%)	0	0	0	0
Injection site pain	2 (33%)	11 (92%)	10 (83%)	1 (17%)	12 (100%)	10 (83%)
Injection site swelling	0	1 (8%)	1 (8%)	0	1 (8%)	0
Systemic solicited adverse events
Arthralgia	0	0	1 (8%)	0	0	1 (8%)
Chills	0	2 (17%)	0	0	0	0
Decreased appetite	0	2 (17%)	1 (8%)	0	0	0
Fatigue	1 (17%)	4 (33%)	3 (25%)	0	1 (8%)	4 (33%)
Headache	2 (33%)	3 (25%)	3 (25%)	1 (17%)	2 (17%)	3 (25%)
Myalgia	0	2 (17%)	1 (8%)	0	0	2 (17%)
All other related AEs occurring in at least two subjects
Aspartate aminotransferase increased	0	0	0	0	2 (17%)	0